RELIZORB test for children needing tube feeding and IV nutrition
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether RELIZORB helps children with short bowel syndrome (SBS), who rely on IV nutrition (and also tube feeding), absorb fats better. It is an open-label study over 90 days, meaning everyone gets the study treatment and outcomes are compared over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 2 to 18, and you must have short bowel syndrome (SBS) with ongoing IV nutrition need
- At least 3 months have passed since your bowel surgery that led to SBS
- You receive IV (parenteral) nutrition for at least 6 months, with a stable need in the last month
- You have a central venous catheter (a long IV line) in place
- You also have a feeding tube and are getting tube feeding through a pump at a compatible rate, and can tolerate enough daily tube feeding to use RELIZORB cartridges (up to 6 per day)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children who are already taking RELiZORB to see how it’s going over time and whether it remains safe and tolerable, with effects on nutrient absorption. It doesn’t change treatment—it mainly looks at outcomes during the next 90 days.
This trial tests a new medicine called PJ009 for people with short bowel syndrome who need intravenous (IV) nutrition support. It aims to help reduce the need for IV nutrition. To join, you must have been dependent on IV nutrition for at least six months and be on a stable schedule.
This trial tests if crofelemer can reduce diarrhea and fluid loss in people with short bowel syndrome who have a stoma (no colon connection) and need intravenous nutrition or fluids. The goal is to see if it improves gut function and quality of life.
This study tests a new treatment called FT1 for people with short bowel syndrome. It aims to help you absorb more nutrients and fluids from food, potentially reducing the need for IV nutrition.
This trial studies whether the Eclipse XL1 system is safe and may help people with short bowel syndrome, in both children and adults. It will check how well the approach works and watch for side effects over the study period.
This trial tests a new medication called glepaglutide to see if it can help people with short bowel syndrome (SBS) who need IV nutrition or fluids at least 3 days a week. The goal is to reduce or even stop the need for these IV treatments.
Hear when a new Short Bowel Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.